Knoflook
    tegen kanker en hart- en vaatziektes.*
Uit
    wel 35 recente onderzoeken naar knoflook blijkt overduidelijk de heel goede
    eigenschappen van knoflook. In het bijzonder zijn de resultaten tegen kanker
    en tegen en bij hart- en vaatziektes. Het verlaagt het cholesterol, de
    bloeddruk, homocysteïne waarden, vermindert aderverkalking en verbetert de
    bloeddoorstroming.
Garlic's
    Efficacy Against Cancer And Heart Disease
Garlic,
    recognized for its healing powers in ancient times, is now being
    rediscovered by medical scientists, who have new evidence of its efficacy
    against cancer and heart disease. Dr. Richard Rivlin, of
    NewYork-Presbyterian Hospital/Weill Cornell Medical Center, is guest
    co-editor of a special March peer-reviewed supplemental issue to The
    Journal of Nutrition. The issue comprises 35 articles representing the
    latest research on garlic -- findings that were first presented at a
    symposium held last year at Georgetown University.
    "Medical texts from China, India, Egypt, Greece and Italy mention
    medical applications of garlic," says Dr. Rivlin, professor of medicine
    at Weill Cornell Medical College, attending physician at
    NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and director of
    the Nutrition Center at the Strang Cancer Prevention Laboratory.
    "Cultures that developed independently came to the same general
    conclusions, namely, that garlic could be administered to provide strength
    and to increase work capacity. Hippocrates, considered the Father of
    Medicine, used garlic as an essential component of one of his therapies."
    Dr. Rivlin believes that while much promising research has been made
    pointing to the disease-preventive and therapeutic effects of garlic, at the
    present time, it should be considered complementary medicine, not
    alternative therapy. "The rapid pace of advances in garlic research
    provides increasing evidence that garlic has significant potential as a
    complement to established therapies."
    New research on the health benefits of garlic, as published in The
    Journal of Nutrition special issue, include the following:
    -- Selenium -- a compound found in garlic -- may be instrumental to garlic's
    anti-cancer properties. ("Cancer Chemoprevention by Garlic and
    Garlic-Containing Sulfur and Selenium Compounds," by Drs. K. El-Bayoumy
    and R. Sinha, Penn. State; Dr. J. Pinto, Cornell-Burke Medical Research
    Institute; and Dr. R. Rivlin, Weill Cornell Medical College)
    -- Garlic may slow the progression of coronary artery calcification in
    patients on statin therapy. ("Aged Garlic Extract Retards Progression
    of Coronary Artery Disease," by Dr. M. Budoff, Harbor-UCLA Medical
    Center)
    -- In addition to its cholesterol-lowering potential,
    blood-pressure-lowering effects, and antioxidant properties, garlic may help
    moderate levels of homocysteine, an amino acid that is a marker for coronary
    artery disease. ("Homocysteine-Lowering Action Is Another Potential
    Cardiovascular Protective Factor of Aged Garlic Extract," by Drs. Y.
    Yeh and S. Yeh, Penn. State)
    -- Garlic may inhibit platelet aggregation -- a major contributing factor to
    cardiovascular disease -- by suppressing calcium mobilization. ("Aged
    Garlic Extract May Inhibit Aggregation in Human Platelets by Suppressing
    Calcium Mobilization," by Drs. G. Allison, G. Lowe, and K. Rahman,
    Liverpool John Moores University, U.K.)
    -- Garlic may reduce pre-cancerous gastric lesions. ("Factorial Trial
    Including Garlic Supplements Assesses Effect in Reducing Precancerous
    Gastric Lesions," by Dr. M. Gail, National Cancer Institute, and Dr. W.
    You, Beijing Institute of Cancer Research)
    -- Garlic may suppress progression of precancerous lesions of the large
    bowel. ("Aged Garlic Extract Has Potential Suppressive Effect on
    Colorectal Adenomas in Humans," by Drs. S. Tanaka, Hiroshima University,
    Japan; K. Haruma, Kawasaki Medical School, Japan; M. Yoshihara, Hiroshima
    University, Japan; G. Kajiyama, Onomichi General Hospital, Japan; K. Kira,
    Wakunaga Pharmaceutical, Japan; H. Amagase, Wakunaga of America; and K.
    Chayama, Hiroshima University, Japan)
    Studies published in the journal were made possible through a variety of
    public and private funding sources.
    http://www.nyp.org
    (  april 2006)